Carducci MA - Search Results

1

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Verheul HM, Qian DZ, Carducci MA, Pili R. Verheul HM, et al. Among authors: carducci ma. Cancer Chemother Pharmacol. 2007 Aug;60(3):329-39. doi: 10.1007/s00280-006-0379-2. Epub 2007 Jan 26. Cancer Chemother Pharmacol. 2007. PMID: 17256134

2

Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines.

Pelidis MA, Carducci MA, Simons JW. Pelidis MA, et al. Among authors: carducci ma. Int J Oncol. 1998 Apr;12(4):889-93. doi: 10.3892/ijo.12.4.889. Int J Oncol. 1998. PMID: 9499451

3

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Nelson WG, et al. Among authors: carducci ma. Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72. doi: 10.1007/pl00014053. Cancer Chemother Pharmacol. 2000. PMID: 10950151 Clinical Trial.

4

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Pili R, et al. Among authors: carducci ma. Cancer Res. 2001 Feb 15;61(4):1477-85. Cancer Res. 2001. PMID: 11245454

5

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.

Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB. Heath EI, et al. Among authors: carducci ma. Cancer Chemother Pharmacol. 2001 Oct;48(4):269-74. doi: 10.1007/s002800100330. Cancer Chemother Pharmacol. 2001. PMID: 11710626 Clinical Trial.

6

Differentiation therapy.

Spira AI, Carducci MA. Spira AI, et al. Among authors: carducci ma. Curr Opin Pharmacol. 2003 Aug;3(4):338-43. doi: 10.1016/s1471-4892(03)00081-x. Curr Opin Pharmacol. 2003. PMID: 12901941 Review.

7

A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.

Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. Sunkara U, et al. Among authors: carducci ma. J Interferon Cytokine Res. 2004 Jan;24(1):37-41. doi: 10.1089/107999004772719891. J Interferon Cytokine Res. 2004. PMID: 14980083 Clinical Trial.

8

A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.

Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN Jr. Lin KS, et al. Bioconjug Chem. 2004 Nov-Dec;15(6):1416-23. doi: 10.1021/bc0498267. Bioconjug Chem. 2004. PMID: 15546210

9

A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation.

Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN Jr. Lin KS, et al. Among authors: carducci ma. Bioconjug Chem. 2005 Jan-Feb;16(1):43-50. doi: 10.1021/bc049820h. Bioconjug Chem. 2005. PMID: 15656574

10

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.

Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Rosenbaum E, et al. Among authors: carducci ma. Clin Cancer Res. 2005 Jun 15;11(12):4437-43. doi: 10.1158/1078-0432.CCR-04-2252. Clin Cancer Res. 2005. PMID: 15958628 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

438 results

Search Page

Filters